Tarsus Pharmaceuticals, Inc. (TARS) Prices 5.5M Share IPO at $16/Sh

Tarsus Pharmaceuticals, Inc., (NASDAQ: TARS) a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions, today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $88.0 million, before underwriting discounts, commissions, and offering expenses payable by Tarsus. In addition, Tarsus has granted the underwriters an option for a period of 30 days to purchase up to 825,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares are being offered and sold by Tarsus.

Tarsus’ common stock is expected to begin trading on The Nasdaq Global Select Market on October 16, 2020 under the symbol “TARS.” The offering is expected to close on or about October 20, 2020, subject to the satisfaction of customary closing conditions.

BofA Securities, Jefferies and Raymond James are acting as joint book-running managers for the offering. LifeSci Capital and Ladenburg Thalmann are acting as co-managers for the offering.

You May Also Be Interested In

• Entrata (ENT) files for proposed IPO
• NU E Power Corp. adds Peter Espig to its board of directors
• NIQ Global Intelligence Plc (NIQ) PT Raised to $25 at UBS